fda rules on compounded semaglutide Novo Nordisk calls out dangers of GLP-1s in new ad fda rules on compounded semaglutide – Compounded "semaglutide" is not FDA-approved

Key reasons GLP-1s require heightened caution in eating disorder populations include: Appetite suppression that may reinforce restrictive behaviors Rapid or significant weight changes that can increase psychological distress Heightened focus on food intake, body cues, or weight-related outcomes Temporary behavioral changes that may mask symptoms rather than address underlying drivers Eating disorders are multifaceted mental health conditions that cannot be effectively treated through appetite or weight changes alone

For Glutathione research procurement, both categories matter

Nat Rev Mol Cell Biol 8(2):139148

But shouldn't dietary therapy always be the context